EHA 2021 | State-of-the-art treatment for HR-MDS
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, outlines state-of-the-art therapies for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Prof. Wei highlights the use of novel immunotherapeutic agents such as magrolimab, which targets CD47, and sabatolimab, which targets TIM-3, as well commenting on the use of BCL-2 inhibitors such as venetoclax. Prof. Wei also compares therapeutic strategies for patients undergoing transplantation and for those not undergoing transplantation. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Andrew Wei, MBBS, PhD, has received research grants from Abbvie, Amgen, AstraZeneca, Celgene/BMS, Novartis, Servier and F. Hoffmann-La Roche; has received honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer, and Servier; has participated in advisory boards for Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer, and Servier; has participated in speakers bureau for Novartis, Abbvie and Celgene/BMS, has participated in consultancy work for Servier; is a former employee of the Walter and Eliza Hall Institute, and is eligible for a fraction of the royalty stream related to Venetoclax.
